CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...